JP2021518149A - 免疫細胞増殖を促進する方法 - Google Patents
免疫細胞増殖を促進する方法 Download PDFInfo
- Publication number
- JP2021518149A JP2021518149A JP2020550874A JP2020550874A JP2021518149A JP 2021518149 A JP2021518149 A JP 2021518149A JP 2020550874 A JP2020550874 A JP 2020550874A JP 2020550874 A JP2020550874 A JP 2020550874A JP 2021518149 A JP2021518149 A JP 2021518149A
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- amino acid
- seq
- homology
- sequence represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 261
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 15
- 239000012634 fragment Substances 0.000 claims abstract description 170
- 238000000034 method Methods 0.000 claims abstract description 144
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims abstract description 120
- 230000001965 increasing effect Effects 0.000 claims abstract description 37
- 230000001737 promoting effect Effects 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 515
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 121
- 150000007523 nucleic acids Chemical class 0.000 claims description 104
- 239000000427 antigen Substances 0.000 claims description 99
- 108091007433 antigens Proteins 0.000 claims description 99
- 102000036639 antigens Human genes 0.000 claims description 99
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 87
- 206010028980 Neoplasm Diseases 0.000 claims description 86
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 83
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 49
- 239000013598 vector Substances 0.000 claims description 41
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 37
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 36
- 102000004127 Cytokines Human genes 0.000 claims description 32
- 108090000695 Cytokines Proteins 0.000 claims description 32
- 102000015696 Interleukins Human genes 0.000 claims description 32
- 108010063738 Interleukins Proteins 0.000 claims description 32
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 31
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 31
- 230000003834 intracellular effect Effects 0.000 claims description 31
- 108010015179 Low Density Lipoprotein Receptor-Related Protein-6 Proteins 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 30
- 230000011664 signaling Effects 0.000 claims description 27
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 26
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 26
- 230000015654 memory Effects 0.000 claims description 26
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 25
- 102100032530 Glypican-3 Human genes 0.000 claims description 24
- 108010002350 Interleukin-2 Proteins 0.000 claims description 24
- 102000000588 Interleukin-2 Human genes 0.000 claims description 24
- 108010015167 Low Density Lipoprotein Receptor-Related Protein-5 Proteins 0.000 claims description 23
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 23
- 239000002609 medium Substances 0.000 claims description 22
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 20
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 19
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 19
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 18
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 17
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 17
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 16
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 16
- 102000003735 Mesothelin Human genes 0.000 claims description 16
- 108090000015 Mesothelin Proteins 0.000 claims description 16
- 210000004698 lymphocyte Anatomy 0.000 claims description 16
- 230000019491 signal transduction Effects 0.000 claims description 16
- 108010002586 Interleukin-7 Proteins 0.000 claims description 15
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 15
- 102100027207 CD27 antigen Human genes 0.000 claims description 14
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 14
- 108091008874 T cell receptors Proteins 0.000 claims description 14
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 14
- 102000001774 Low Density Lipoprotein Receptor-Related Protein-6 Human genes 0.000 claims description 13
- 102100030704 Interleukin-21 Human genes 0.000 claims description 12
- 108010074108 interleukin-21 Proteins 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 12
- 210000003289 regulatory T cell Anatomy 0.000 claims description 12
- 108090000172 Interleukin-15 Proteins 0.000 claims description 11
- 102000003812 Interleukin-15 Human genes 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 9
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 9
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 8
- 102100033467 L-selectin Human genes 0.000 claims description 8
- 206010027406 Mesothelioma Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 229920000728 polyester Polymers 0.000 claims description 8
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 7
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 7
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 7
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 7
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000012239 gene modification Methods 0.000 claims description 7
- 230000002147 killing effect Effects 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 6
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 230000005017 genetic modification Effects 0.000 claims description 6
- 235000013617 genetically modified food Nutrition 0.000 claims description 6
- 239000013612 plasmid Substances 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 108090000978 Interleukin-4 Proteins 0.000 claims description 5
- 102000004388 Interleukin-4 Human genes 0.000 claims description 5
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 5
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 5
- 230000004952 protein activity Effects 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079322 interferon Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000005909 tumor killing Effects 0.000 claims description 2
- 102000001770 Low Density Lipoprotein Receptor-Related Protein-5 Human genes 0.000 claims 12
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims 4
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 4
- 102000000704 Interleukin-7 Human genes 0.000 claims 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 88
- 108090000623 proteins and genes Proteins 0.000 description 59
- 102000004169 proteins and genes Human genes 0.000 description 46
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- 230000008685 targeting Effects 0.000 description 19
- 102000000853 LDL receptors Human genes 0.000 description 17
- 108010001831 LDL receptors Proteins 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 15
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 15
- 102100021592 Interleukin-7 Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 10
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 description 10
- 229940047122 interleukins Drugs 0.000 description 10
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 9
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000031146 intracellular signal transduction Effects 0.000 description 5
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000010956 Glypican Human genes 0.000 description 3
- 108050001154 Glypican Proteins 0.000 description 3
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- GLNADSQYFUSGOU-UHFFFAOYSA-J chembl1640 Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-UHFFFAOYSA-J 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 2
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 2
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 2
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 description 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 2
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 229940126530 T cell activator Drugs 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 2
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 2
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000051957 human ERBB2 Human genes 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000006054 immunological memory Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- XIIHIHJIEDXAJC-UHFFFAOYSA-N 1-nitro-4,5-dihydroimidazole Chemical class [O-][N+](=O)N1CCN=C1 XIIHIHJIEDXAJC-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101800001148 Delta-peptide Proteins 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100034190 Glypican-1 Human genes 0.000 description 1
- 102100021194 Glypican-6 Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101001070736 Homo sapiens Glypican-1 Proteins 0.000 description 1
- 101001040704 Homo sapiens Glypican-6 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 1
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 1
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 description 1
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- RUXQWZJWMCHCHH-IZZDOVSWSA-N [(e)-1-pyridin-2-ylethylideneamino]urea Chemical compound NC(=O)N\N=C(/C)C1=CC=CC=N1 RUXQWZJWMCHCHH-IZZDOVSWSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940072174 amphenicols Drugs 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 102000055104 bcl-X Human genes 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 101150058049 car gene Proteins 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 102000048373 human GPC3 Human genes 0.000 description 1
- 102000046935 human TNFRSF17 Human genes 0.000 description 1
- 102000050327 human TNFRSF9 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000009607 mammography Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000006833 reintegration Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/53—Liver
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193020A JP2025023986A (ja) | 2018-03-26 | 2024-11-01 | 免疫細胞増殖を促進する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810251875.7 | 2018-03-26 | ||
| CN201810251875 | 2018-03-26 | ||
| PCT/CN2019/079576 WO2019184886A1 (zh) | 2018-03-26 | 2019-03-25 | 促进免疫细胞增殖的方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193020A Division JP2025023986A (ja) | 2018-03-26 | 2024-11-01 | 免疫細胞増殖を促進する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021518149A true JP2021518149A (ja) | 2021-08-02 |
| JP2021518149A5 JP2021518149A5 (https=) | 2024-11-21 |
Family
ID=68059463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550874A Pending JP2021518149A (ja) | 2018-03-26 | 2019-03-25 | 免疫細胞増殖を促進する方法 |
| JP2024193020A Pending JP2025023986A (ja) | 2018-03-26 | 2024-11-01 | 免疫細胞増殖を促進する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193020A Pending JP2025023986A (ja) | 2018-03-26 | 2024-11-01 | 免疫細胞増殖を促進する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12005080B2 (https=) |
| EP (1) | EP3778876A4 (https=) |
| JP (2) | JP2021518149A (https=) |
| CN (1) | CN111918964B (https=) |
| WO (1) | WO2019184886A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022206975A1 (zh) * | 2021-04-02 | 2022-10-06 | 原启生物科技(上海)有限责任公司 | Cldn18.2抗原结合蛋白及其用途 |
| CN117136199A (zh) * | 2021-04-27 | 2023-11-28 | 原启生物科技(上海)有限责任公司 | 靶向bcma的嵌合抗原受体及其应用 |
| WO2023030272A1 (zh) * | 2021-08-30 | 2023-03-09 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
| JP2025505933A (ja) * | 2022-01-06 | 2025-03-05 | オリセル セラピューティクス カンパニー リミテッド | Ｍｓｌｎを標的とする抗原結合タンパク質及びその使用 |
| CN116656614A (zh) * | 2022-02-17 | 2023-08-29 | 杭州乾合细胞生物科技有限公司 | 一种靶向Her-2的CAR-NK细胞及其应用 |
| CN114891115B (zh) * | 2022-02-18 | 2025-07-18 | 杭州美中疾病基因研究院有限公司 | 一种car细胞疗法用核酸构建体及其慢病毒载体、细胞制剂和应用 |
| WO2024251290A1 (en) * | 2023-06-09 | 2024-12-12 | Suzhou Cure Genetics Biosciences Co., Limited | Engineered immune cells and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3169703T4 (fi) * | 2014-07-16 | 2024-03-01 | Hinrich Abken | Kimeerinen antigeenireseptori ja sen käyttö |
| WO2017040287A1 (en) * | 2015-08-28 | 2017-03-09 | Serpin Pharma, Llc | Methods for treatment of diseases |
| GB201516972D0 (en) * | 2015-09-25 | 2015-11-11 | Epiontis Gmbh | LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells |
| KR20180063320A (ko) * | 2015-10-20 | 2018-06-11 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| WO2018009972A1 (en) * | 2016-07-14 | 2018-01-18 | Peter Maccallum Cancer Institute | Chimeric antigen receptor modified t cells |
| EP3600418A4 (en) * | 2017-03-24 | 2021-01-13 | Yale University | LOW DENSITY LIPOPROTEIN RECEPTOR-BOUND PROTEIN-5 INHIBITION WHICH SUPPRESSES TUMOR FORMATION |
| CN108392492B (zh) * | 2017-12-28 | 2021-01-01 | 中国人民解放军第二军医大学东方肝胆外科医院 | Ldlr过表达在nk细胞过继治疗中的应用 |
-
2019
- 2019-03-25 WO PCT/CN2019/079576 patent/WO2019184886A1/zh not_active Ceased
- 2019-03-25 JP JP2020550874A patent/JP2021518149A/ja active Pending
- 2019-03-25 EP EP19776983.9A patent/EP3778876A4/en active Pending
- 2019-03-25 US US17/040,865 patent/US12005080B2/en active Active
- 2019-03-25 CN CN201980022452.0A patent/CN111918964B/zh active Active
-
2024
- 2024-11-01 JP JP2024193020A patent/JP2025023986A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025023986A (ja) | 2025-02-19 |
| CN111918964A (zh) | 2020-11-10 |
| US20210106620A1 (en) | 2021-04-15 |
| CN111918964B (zh) | 2025-05-30 |
| WO2019184886A1 (zh) | 2019-10-03 |
| EP3778876A4 (en) | 2022-01-12 |
| US12005080B2 (en) | 2024-06-11 |
| EP3778876A1 (en) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518149A (ja) | 免疫細胞増殖を促進する方法 | |
| US12042515B2 (en) | Killer cell capable of efficiently and stably expressing antibody, and uses thereof | |
| EP3389682B1 (en) | Group b adenovirus encoding an anti-tcr-complex antibody or fragment | |
| CN113286874A (zh) | 嵌合抗原受体(CARs)组合物及使用方法 | |
| CN107523549A (zh) | 一种高效稳定表达激活型抗体的car‑t细胞及其用途 | |
| CN113677353A (zh) | 修饰细胞的扩增及其用途 | |
| JP2017522859A (ja) | グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用 | |
| JPWO2019124468A1 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ−７、及びｃｃｌ１９を発現する免疫担当細胞 | |
| EP4013431A1 (en) | Combination therapy with gold controlled transgenes | |
| EP3833682A1 (en) | Suicide module compositions and methods | |
| KR20240055714A (ko) | 돌연변이 il-15 조성물 및 이의 방법 | |
| IL292355A (en) | Compositions and methods for in vitro activation and expansion of serial killer t-cell populations and passive vaccination of a cancer patient with tumor cell-killing cells | |
| WO2020028654A1 (en) | Combined invasion and cytotoxicity assay using chemokine secreting target cells | |
| WO2025130934A1 (zh) | 表达膜结合型il-15融合蛋白的工程化til及其应用 | |
| US20240400989A1 (en) | Method for promoting proliferation of immune cells | |
| WO2023076523A1 (en) | Chimeric adaptor polypeptides | |
| WO2022260968A1 (en) | Compositions and methods for activating natural killer cells | |
| US20220389076A1 (en) | Modified immune cell and use thereof | |
| EP4232051A1 (en) | Mercury controlled gene expression | |
| TW202140790A (zh) | 病毒載體轉導細胞的方法 | |
| WO2023056194A2 (en) | Compositions and methods for anti-tnmuc1 gold car t-cells | |
| CN115704039A (zh) | 包含编码抗原结合分子的多核苷酸和靶向ecm试剂的多核苷酸的多核苷酸及修饰细胞 | |
| US20240209058A1 (en) | Mesothelin-specific T cell Receptors and Methods of Using Same | |
| HK40104411B (zh) | 表达膜结合型il-15融合蛋白的工程化til及其应用 | |
| HK40104411A (zh) | 表达膜结合型il-15融合蛋白的工程化til及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201007 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201020 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20201007 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220118 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230615 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230704 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231004 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240207 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20240404 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240702 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20241101 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241112 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20241122 |